In vitro activity of LB20304 against 1,231 clinical isolates was evaluated and compared with those of ciprofloxacin, sparfloxacin, lomefloxacin, and ofloxacin. LB20304 demonstrated the most potent activity against gram-positive bacteria. It was 32-to 64-fold more active than ciprofloxacin against methicillinsusceptible Staphylococcus aureus, methicillin-resistant S. aureus, methicillin-resistant Staphylococcus epidermidis, and Streptococcus pneumoniae (penicillin G resistant). LB20304 was also highly active against most members of the family Enterobacteriaceae. Its activity was more potent than those of sparfloxacin, ofloxacin, and lomefloxacin and comparable to that of ciprofloxacin. The protective activities of LB20304 against systemic infections caused by gram-positive bacteria in mice were superior to those of ciprofloxacin and sparfloxacin. Against infections by gram-negative bacteria, LB20304 was slightly less active than ciprofloxacin.
A number of new quinolone derivatives, such as norfloxacin, ofloxacin, enoxacin, ciprofloxacin, lomefloxacin, and fleroxacin, have been recently developed and introduced into the market. These new fluoroquinolones have become important chemotherapeutic agents, especially for seriously infected patients requiring potent oral drugs (16) . However, these new fluoroquinolone agents possess only moderate activities against many gram-positive cocci, including staphylococci and streptococci, which are major pathogenic strains for respiratory tract infections (12, 15) . Since it has been suggested that increasing resistance to fluoroquinolones is due to the moderate activities of these drugs against gram-positive bacteria (2, 6, 7) , recent efforts have been directed toward the synthesis of novel quinolone compounds that can provide improved activities against gram-positive organisms while retaining the broad-spectrum activity of ciprofloxacin (5, 11, 14) . LB20304, 7-(3-aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro- [1, 8] -naphthyridine-3-carboxylic acid, is a new quinolone antibacterial agent synthesized at LG Chemical Ltd., Taejon, Korea (Fig. 1 ). This compound showed broad-spectrum antibacterial activity. Especially, it exhibited potent in vitro and in vivo activities against gram-positive bacteria.
In this study, we compared in vitro activities of LB20304 with those of ciprofloxacin, sparfloxacin, lomefloxacin, and ofloxacin against clinical isolates. The comparative in vivo efficacy of LB20304 against systemic infections in mice was also investigated.
(This work was presented in part at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy [10] .) Antimicrobial agents. LB20304 was synthesized at the Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd. All quinolones used for comparison were obtained directly from their manufacturers.
Bacterial strains. Test organisms used in this study were originally isolated from human clinical specimens. These were collected from several hospitals in Korea from 1992 to 1994. All isolates were stored frozen at Ϫ70ЊC.
Susceptibility tests. MICs of LB20304 were determined by the agar dilution method as described by the National Committee for Clinical Laboratory Standards (9) . Mueller-Hinton medium (Difco Laboratories, Detroit, Mich.) was used for testing aerobic and facultative organisms. For Streptococcus pneumoniae and Streptococcus pyogenes, Mueller-Hinton broth was supplemented with 5% defibrinated sheep blood. Test strains were grown for 18 h in Mueller-Hinton broth and diluted with the same fresh medium to a density of approximately 10 7 CFU/ml. These strains were applied to MuellerHinton agar plates containing serial dilutions of the antimicrobial agents, by using an automatic MIC-2000 multipin inoculator (Dynatech Laboratories, Inc., Alexandria, Va.) to yield 10 4 CFU per spot. The MIC was considered to be the lowest concentration that completely inhibited growth on agar plates, disregarding a single colony or a faint haze caused by the inoculum.
The comparative in vitro antibacterial activities of LB20304 are shown in Table 1 . LB20304 showed the most potent antibacterial activities among the compounds tested against grampositive bacteria. Against methicillin-susceptible strains of Staphylococcus aureus (MSSA), LB20304, with a MIC at which 90% of the isolates were inhibited (MIC 90 ) of 0.063 g/ml, was 32-fold more active than ciprofloxacin. LB20304 also demon- In vivo activity. In vivo activity of LB20304 was determined against systemic infections in mice. Test organisms for infection were cultured in Tryptic Soy Agar Medium (Difco) at 35ЊC for 18 h and were suspended in 5 or 7.5% gastric mucin (Difco). Male ICR mice weighing 19 to 21 g (Biotech Research Institute, LG Chem Ltd.) were injected intraperitoneally with 0.5 ml of the bacterial suspension corresponding to an inoculum range of 5 to 10 times the minimal lethal dose of bacteria. Four dose levels were used for each antibiotic, depending on the in vitro antimicrobial activity of the compound. Antibiotics at various dose regimens were orally administered to mice twice at 1 and 4 h postinfection. Mortality was recorded for 7 days, and the median effective dose needed to protect 50% of the mice (ED 50 ) was calculated by the probit method (1). All untreated mice died within 2 days after infection.
The protective effects of LB20304 against systemic infections were compared with those of ciprofloxacin and sparfloxacin (Table 2 ). LB20304 exhibited the most potent protective effects against systemic infections caused by gram-positive bacteria. Against S. aureus giorgio infection, the ED 50 s of LB20304, ciprofloxacin, and sparfloxacin were 1.68, 14.0, and 2.27 mg/kg of body weight, respectively. Against S. pyogenes 77A and S. pneumoniae III, oral therapy with LB20304 yielded ED 50 s of 10.4 and 7.64 mg/kg, respectively, while oral ciprofloxacin therapy was inefficient at doses of up to 140 and 200 mg/kg, respectively. Against P. aeruginosa 1912E, LB20304 with an ED 50 of 2.19 mg/kg showed an efficacy comparable to that of ciprofloxacin (ED 50 , 3.11 mg/kg). LB20304 (ED 50 , 0.47 mg/kg) was slightly less active than ciprofloxacin (ED 50 , 0.2 mg/kg) and sparfloxacin (ED 50 , 0.3 mg/kg) against E. coli. Against P. mirabilis 1315E, the ED 50 s of LB20304, ciprofloxacin, and sparfloxacin were 4.33, 0.47, and 3.91 mg/kg, respectively. LB20304 (ED 50 , 7.96 mg/kg) was less active than ciprofloxacin (ED 50 , 1.45 mg/kg) against S. marcescens 1826E but as active as sparfloxacin (ED 50 , 10.3 mg/kg). Against M. morganii 1375E, LB20304 (ED 50 , 6.74 mg/kg) was less active than ciprofloxacin (ED 50 , 1.01 mg/kg) and sparfloxacin (ED 50 , 1.18 mg/kg). LB20304, with ED 50 s of 4.86 and 1.52 mg/kg, respectively, was slightly less active than ciprofloxacin and sparfloxacin against A. calcoaceticus Ac-54 and E. cloacae 1375E. The protective effect of LB20304 in the mouse infection model was well correlated with its in vitro activity.
Although fluoroquinolones have been recognized as effective antibiotics against gram-negative and gram-positive bacte- LB20304 demonstrated an advantage in the spectrum of activity because it had improved activity against gram-positive pathogens, such as MRSA, MRSE, S. pneumoniae, S. pyogenes, and E. faecalis, with potent activity against gram-negative organisms still being maintained. The good activity of LB20304 against gram-positive organisms is associated with its novel oxime functionalized aminomethyl-pyrrolidine side chain (8) . It has been reported that quinolones with a substituted 3-aminomethyl-pyrrolidinyl side chain at C-7 show greatly enhanced activity against gram-positive pathogens both in vitro and in vivo (3) . On the other hand, other previous reports have shown that naphthyridones were often less active than their quinolone counterparts (3, 4, 13) . However, it is remarkable that LB20304, a new fluoronaphthyridone containing a novel pyrrolidine side chain at C-7, has activity against gram-positive and gram-negative bacteria comparable to those of its quinolone counterparts which have the same pyrrolidine side chain (8) . In addition, LB20304 demonstrated good pharmacokinetic profiles after oral administration in animals (10) . These characteristics suggest a significant therapeutic potential for this compound.
In view of its improved activities and pharmacokinetic profiles in animals, the clinical usefulness of this compound should be established by further studies.
